Biocept (BIOC) Reports Q4 Loss of $0.87/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Biocept Reports Fourth Quarter 2014 Financial Results
March 9, 2015 4:05 PM EDTSAN DIEGO, March 9, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced its financial results for the fourth quarter and year ended December 31, 2014.
Fourth Quarter and Recent Highlights
Strengthened the Company's product line of non-small cell lung cancer (NSCLC) diagnostics through multiple product launches, including: The launch of... MoreBiocept Reports Fourth Quarter 2014 Financial Results
March 9, 2015 4:05 PM EDTSAN DIEGO, March 9, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced its financial results for the fourth quarter and year ended December 31, 2014.
Fourth Quarter and Recent Highlights
Strengthened the Company's product line of non-small cell lung cancer (NSCLC) diagnostics through multiple product launches, including: The launch of... MoreNext Generation Sequencing Veteran Joins Biocept
March 5, 2015 8:30 AM ESTSAN DIEGO, March 5, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced that Jason Poole, Ph.D. has joined the Company as Senior Director, Molecular Assay Development.
Dr. Poole brings extensive molecular diagnostic development experience to Biocept. Previously, Dr. Poole was Director, R&D at Trovagene. He has also worked with EMD Millipore as well as... More
